You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, April 2016
|
| DOI | 10.1186/s40425-016-0129-x |
| Pubmed ID | |
| Authors |
Melina E. Marmarelis, Meredith R. Davis, Nilay S. Sethi, Katherine M. Krajewksi, Rana R. McKay, Toni K. Choueiri, Patrick A. Ott |
| Abstract |
Blockade of the immunological checkpoint programmed death 1 (PD-1) using monoclonal antibodies has shown robust anti-tumor activity across a broad range of solid and hematological malignancies including melanoma and renal cell carcinoma (RCC). Characteristic markers such as the presence of tumor infiltrating lymphocytes, PD-L1 status, and mutational load may be equally or even more important in predicting clinical benefit from PD-1 pathway blockade than tumor histology. This case of a patient with concurrent metastatic melanoma and metastatic RCC, both of which were controlled for more than a year after a single dose of the anti-PD-1 antibody pembrolizumab, illustrates the potential to simultaneously treat distinct immunogenic tumors with anti-PD-1 agents. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 2 | 17% |
| United States | 2 | 17% |
| Turkey | 1 | 8% |
| Hong Kong | 1 | 8% |
| Unknown | 6 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 67% |
| Practitioners (doctors, other healthcare professionals) | 2 | 17% |
| Scientists | 2 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 17% |
| Researcher | 5 | 14% |
| Student > Ph. D. Student | 5 | 14% |
| Student > Bachelor | 4 | 11% |
| Student > Postgraduate | 2 | 6% |
| Other | 5 | 14% |
| Unknown | 9 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 31% |
| Agricultural and Biological Sciences | 6 | 17% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Unspecified | 1 | 3% |
| Mathematics | 1 | 3% |
| Other | 4 | 11% |
| Unknown | 9 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2016.
All research outputs
#5,188,039
of 25,373,627 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,320
of 3,421 outputs
Outputs of similar age
#75,887
of 313,420 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#9
of 15 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,420 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.